|
[1]YOUNOSSI ZM, BLISSETT D, BLISSETT R, et al.The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe[J].Hepatology, 2016, 64 (5) :1577-1586.
|
|
[2]BARGIGGIA S, MACONI G, ELLI M, et al.Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease:Study of 511 subjects at a single center[J].J Clin Gastroenterol, 2003, 36 (5) :417-420.
|
|
[3] BESSISSOW T, LE NH, ROLLET K, et al.Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease[J].Inflamm Bowel Dis, 2016, 22 (8) :1937-1944.
|
|
[4]CAPPELLO M, RANDAZZO C, BRAVATI, et al.Liver function test abnormalities in patients with inflammatory bowel diseases:A hospital-based survey[J].Clin Med Insights Gastroenterol, 2014, 7:25-31.
|
|
[5]CHANDRASHEKARAN V, SETH RK, DATTAROY D, et al.HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease[J].Redox Biol, 2017, 13:8-19.
|
|
[6]BESSISSOW T, LE NH, ROLLET K, et al.Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease[J].Inflamm Bowel Dis, 2016, 22 (8) :1937-1944.
|
|
[7]BOSCH DE, YEH MM.Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease[J].Hum Pathol, 2017, 69:55-62.
|
|
[8]GLASSNER K, MALATY HM, ABRAHAM BP.Epidemiology and risk factors of nonalcoholic fatty liver disease among patients with inflammatory bowel disease[J].Inflamm Bowel Dis, 2017, 23 (6) :998.
|
|
[9]SAGAMI S, UENO Y, TANAKA S, et al.Significance of nonalcoholic fatty liver disease in Crohn's disease:A retrospective cohort study[J].Hepatol Res, 2017, 47 (9) :872-881.
|
|
[10]SCHRDER T, SCHMIDT KJ, OLSEN V, et al.Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment[J].Eur JGastroenterol Hepatol, 2015, 27 (6) :698-704.
|
|
[11]SOURIANARAYANANE A, GARG G, SMITH TH, et al.Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease[J].J Crohns Colitis, 2013, 7 (8) :e279-e285.
|
|
[12]SAROLI PC, RESTELLINI S, CHAO CY, et al.Screening for nonalcoholic fatty liver disease in inflammatory bowel diseases:A cohort study using transient elastography[J].Inflamm Bowel Dis, 2018.[Epub ahead of print]
|
|
[13]DOLINSKY VW, DOUGLAS DN, LEHNER R, et al.Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone[J].Biochem J, 2004, 378 (3) :967-974.
|
|
[14]D'SOUZA AM, BEAUDRY JL, SZIGIATO AA, et al.Consumption of a high-fat diet rapidly exacerbates the development of fatty liver disease that occurs with chronically elevated glucocorticoids[J].Am J Physiol Gastrointest Liver Physiol, 2012, 302 (8) :850-863.
|
|
[15]HUBEL JM, SCHMIDT SA, MASON RA, et al.Influence of plasma cortisol and other laboratory parameters on nonalcoholic fatty liver disease[J].Horm Metab Res, 2015, 47 (7) :479-484.
|
|
[16]LAPUMNUAYPOL K, KANJANAHATTAKIJ N, PISARCIK D, et al.Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease:A meta-analysis[J].Eur JGastroenterol Hepatol, 2018, 30 (8) :854-860.
|
|
[17]RUIZ AG, CASAFONT F, CRESPO J, et al.Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients:Evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis[J].Obes Surg, 2007, 17 (10) :1374-1380.
|
|
[18]BARBUIO R, MILANSKI M, BERTOLO MB, et al.Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet[J].J Endocrinol, 2007, 194 (3) :539-550.
|
|
[19]KOCA SS, BAHCECIOGLU IH, POYRAZOGLU OK, et al.The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine-and choline-deficient diet[J].Inflammation, 2008, 31 (2) :91-98.
|
|
[20]YALCIN M, AKARSU M, CELIK A, et al.A comparison of the effects of infliximab, adalimumab, and pentoxifylline on rats with non-alcoholic steatohepatitis[J].Turk J Gastroenterol, 2014, 25 (Suppl 1) :167-175.
|
|
[21]ADAMS LA, ZEIN CO, ANGULO P, et al.A pilot trial of pentoxifylline in nonalcoholic steatohepatitis[J].Am J Gastroenterol, 2004, 99 (12) :2365-2368.
|
|
[22]ANGELICO M, DELLA GP.Review article:Hepatobiliary complications associated with total parenteral nutrition[J].Aliment Pharmacol Ther, 2000, 14 (Suppl 2) :54-57.
|
|
[23]FENG G, NIU CY.Advances in the treatment of nonalcoholic fatty liver disease[J].J Clin Hepatol, 2017, 33 (12) :2433-2438. (in Chinese) 冯巩, 牛春燕.非酒精性脂肪性肝病的治疗进展[J].临床肝胆病杂志, 2017, 33 (12) :2433-2438.
|
|
[24]NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al.Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT) :Amulticentre, randomised, placebo-controlled trial[J].Lancet, 2015, 385 (9972) :956-965.
|
DownLoad: